AI-Driven Antibody Screening Services

Are you currently facing long drug development cycles, challenges in identifying high-affinity candidates, or difficulties in optimizing antibody specificity? Our AI-Driven Antibody Screening Service accelerates therapeutic discovery by enhancing data-driven screening to yield more candidate antibody sequences.

Why AI-based Antibody Screening?

Every year 2500 discovery projects fail to find strong binders with biological effects because of insufficient diversity: in vitro screening starts with a limited set of antibodies and 90% of the binders are lost due to limitations of the process. New antibody panels generated by AI are a source of candidates with new binding modalities and potentially new therapeutic modes-of-action. Typically, AI screening can generate 10 times more antibody sequence clusters than a laboratory-based approach alone, resulting in increased diversity of antibody sequences and target epitope binding which equals greater opportunity to optimize receptor agonism.

Fig.1 Artificial intelligence for antibody screening and discovery.

Enhance Your Project with Our AI-Driven Antibody Screening Service

Creative Biolabs' AI-Driven Antibody Screening Service delivers precise, high-quality antibody candidates tailored to your specific therapeutic needs. We provide a streamlined path from target identification to lead candidate selection, significantly reducing the time and resources typically required in traditional antibody discovery. Our solutions transcend traditional screening boundaries, delivering unmatched speed and precision in identifying optimal binders.

Workflow

Explore Our Assistance – Schedule a Consultation

Introduction of AI-Driven Antibody Screening Service

Antibody therapeutics have revolutionized medicine, yet their discovery remains a complex, time-consuming, and resource-intensive endeavor. Traditional screening methods often struggle with vast library sizes and the need for high-throughput validation. AI-Driven Antibody Screening represents a paradigm shift, harnessing the power of artificial intelligence and machine learning to rapidly identify, optimize, and validate antibody candidates. This technology, including our Antibody De Novo Design Platform, revolutionizes the process by predicting binding affinities and structures with unprecedented speed and accuracy, significantly accelerating the journey from target to therapeutic.

Our Services

• AI-Driven Antibody Characterization Service: Utilize AI models for in silico screening of extensive antibody sequence libraries, employing approaches such as molecular docking and molecular dynamics simulations enhanced by AI analysis. This methodology facilitates the rapid identification and enrichment of antibody candidates exhibiting high binding affinity, specificity, or distinct functional potentials.
• AI-Driven HTS Optimization & Integration Service: AI analysis of historical screening data, target traits, and experimental conditions guides the intelligent design and optimization of high-throughput screening plans, encompassing reagent choice, reaction conditions, and detection metrics, to enhance screening efficiency and success rates.
• Antibody Target Validation Service: High-potential antibodies identified by AI undergo wet-lab verification, including precise affinity and functional testing, with resulting data fed back into AI models and databases to refine prediction algorithms and screening strategies, creating a data-driven intelligent closed loop.

Why Choose Us?

Creative Biolabs stands at the forefront of AI-driven antibody discovery, offering unparalleled advantages that translate into faster, more efficient, and more successful therapeutic development for our clients. Our unique features include:

• Cutting-Edge AI and Deep Learning: We utilize advanced deep learning algorithms for highly accurate prediction of antibody-antigen binding affinities and 3D structures, significantly accelerating the identification of lead candidates.
• Proprietary Antibody De Novo Design Platform: Our innovative platform, coupled with extensive and diverse synthetic libraries, allows for the generation and screening of novel antibody sequences, which are ideal building blocks for complex therapeutic formats due to their compact size and favorable biophysical properties.
• Integrated Computational and Experimental Workflow: Unlike purely in silico approaches, Creative Biolabs combines AI-driven screening with rigorous experimental validation to ensure the high accuracy and reliability of our predictions, providing empirically verified results.
• Accelerated Development and Manufacturing: Our AI-enhanced process streamlines the discovery phase, leading to significant time and cost savings.

Case Study

In an AI-augmented discovery initiative, the diversity of antibody clusters targeting the HIV GP140 antigen was increased by a factor of 13.

Antigen:

The study focused on a biotinylated Avi-tagged BG505 gp140 trimer, incorporating a redesigned HR1 bend.

Data Generation:

The project utilized Ion Torrent PGM sequencing and next-generation sequencing (NGS) of a diverse Homo sapiens antibody phage library.

Process:

- Data were meticulously cleaned and filtered for accurate analysis.

- Unique sequences, totaling 1,823, were identified, alongside 43,172 total counts.

- Clustering was performed based on sequence similarity and enrichment factors.

Results:

- A comparative analysis of traditional screening methods via random sampling of 100 clones against NGS of the final pan combined with clustering revealed a twofold increase in antibody diversity.

- Further comparison, evaluating traditional screening versus NGS across multiple rounds with clustering, demonstrated a remarkable 13-fold increase in diversity.

Creative Biolabs is specialized in designing and performing high-quality custom AI-based antibody screening assays, with different formats, endpoints, parameters, to satisfy any specific requirement at a most competitive price. For more detailed information, please feel free to contact us or directly sent us an inquiry.